Skip to main content
Equibles
TGTX logo

TGTX · Tg Therapeutics, Inc. · Analyst Estimates

Track TGTX — free

Use TGTX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research TGTX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$57.35 -0.05 (-0.09%) Q2 2026 earnings call transcript
S&P 600 member Russell 2000 member Rebalance outlook locked
Market Cap
$8.83B
Shares
153.07M
Volume · Oct 29 998.67K Avg daily vol (3M) 1.89M

Analyst Estimates

Compare analyst forecasts for Tg Therapeutics, Inc. across metrics and forecast periods.

Estimates are grouped by forecast period, with low, average and high together. A dash means that statistic is not available.

Compiled consensus

These figures are a compiled consensus of analyst forecasts, not a survey the company published itself. Every figure is the statistic the source states; averages are means, never medians.

Captured 2026-10-24 00:45 UTC · Publication dates shown per estimate · 8 metric / period groups

FY ending 2026-12-31

Analyst estimates for FY ending 2026-12-31
Metric Low Average High Analyst count Average, 7 days ago Average, 30 days ago Average, 60 days ago Average, 90 days ago Estimates lowered, last 7 days Estimates lowered, last 30 days Estimates raised, last 7 days Estimates raised, last 30 days
EPS
USD
Publication date not stated
0.70
0.95
1.32
4
0.95
0.95
1.00
1.61
3
3
0
0
Revenue
USD
Publication date not stated
950.00M
960.26M
982.63M
8
 — — — — — — — —

FY ending 2027-12-31

Analyst estimates for FY ending 2027-12-31
Metric Low Average High Analyst count Average, 7 days ago Average, 30 days ago Average, 60 days ago Average, 90 days ago Estimates lowered, last 7 days Estimates lowered, last 30 days Estimates raised, last 7 days Estimates raised, last 30 days
EPS
USD
Publication date not stated
2.16
2.71
3.96
5
2.71
2.97
3.13
3.28
3
2
0
2
Revenue
USD
Publication date not stated
1.22B
1.32B
1.44B
8
 — — — — — — — —

Q ending 2026-09-30

Analyst estimates for Q ending 2026-09-30
Metric Low Average High Analyst count Average, 7 days ago Average, 30 days ago Average, 60 days ago Average, 90 days ago Estimates lowered, last 7 days Estimates lowered, last 30 days Estimates raised, last 7 days Estimates raised, last 30 days
EPS
USD
Publication date not stated
0.19
0.26
0.35
4
0.26
0.33
0.34
0.43
2
2
0
0
Revenue
USD
Publication date not stated
232.00M
245.45M
255.00M
8
 — — — — — — — —

Q ending 2026-12-31

Analyst estimates for Q ending 2026-12-31
Metric Low Average High Analyst count Average, 7 days ago Average, 30 days ago Average, 60 days ago Average, 90 days ago Estimates lowered, last 7 days Estimates lowered, last 30 days Estimates raised, last 7 days Estimates raised, last 30 days
EPS
USD
Publication date not stated
0.33
0.41
0.45
3
0.41
0.45
0.45
0.53
2
2
1
0
Revenue
USD
Publication date not stated
259.60M
269.46M
283.00M
8
 — — — — — — — —
Key facts CIK 1001316 CUSIP 88322Q108 13F (30d) 118 filings 112 filers Visit website Investor relations